Skip to content
Clinical Trials – home
Instytut Matki I Dziecka
Sponsor

Instytut Matki I Dziecka

Poland Ul Marcina Kasprzaka 17 A, 01-211 Warsaw, Poland

About the sponsor

Clinical research at Instytut Matki I Dziecka includes treatment-focused studies in refractory primary bone tumors, with attention to Ewing's sarcoma, high-grade osteosarcoma, and relapsed/refractory osteosarcoma. The work is centred on improving disease control in children and adolescents with difficult-to-treat skeletal malignancies.

  • Refractory primary bone tumors
  • Ewing's sarcoma
  • Osteosarcoma

Research interests also extend to event-free survival and the relationship between clinical outcomes and molecular characteristics of the tumour.

About Specializations

Instytut Matki I Dziecka runs clinical trials in conditions such as Erdheim-Chester disease, Rosai-Dorfman syndrome, Langerhans cell sarcoma, Langerhans' cell histiocytosis, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

7 clinical trials

Osteosarcoma

Recruiting
Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Mifamurtide
  • Sponsor:Instytut Matki I Dziecka

Ewing's sarcoma

Recruiting
Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Naxitamab
  • Sponsor:Instytut Matki I Dziecka
Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Valaciclovir
  • Sponsor:Instytut Matki I Dziecka

Osteosarcoma metastatic+3

Not recruiting
Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Regorafenib
  • Sponsor:Instytut Matki I Dziecka

Erdheim-Chester disease+3

Not recruiting
Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Fludeoxyglucose (18F)
  • Sponsor:Instytut Matki I Dziecka

Erdheim-Chester disease+3

Not recruiting
Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Trametinib Dimethyl Sulfoxide
  • Sponsor:Instytut Matki I Dziecka

Erdheim-Chester disease+3

Not recruiting
Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Vemurafenib
  • Sponsor:Instytut Matki I Dziecka

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).